Discounted Cash Flow (DCF) Analysis Levered

BiondVax Pharmaceuticals Ltd. (BVXV)

$1.82

+0.01 (+0.55%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 1.82
Beta 2.462
Diluted Shares Outstanding 10.75
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 15.53%
Risk-Free Rate
Market Risk Premium
Cost of Equity 15.432
Total Debt 69.74
Total Equity 19.56
Total Capital 89.30
Debt Weighting 78.09
Equity Weighting 21.91
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 15.51
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 15.70
Equity Value -
Shares Outstanding 10.75
Equity Value Per Share -